An Official Website of the United States Government
Company Information:
Name:
PAXVAX, INC.
Address:
3985A SORRENTO VALLEY BLVD
SAN DIEGO, CA 92121-
SAN DIEGO, CA 92121-
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Ad4 vectored HIV-Env vaccines with improved immunogenicity
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Marc J. Gurwith
Award Amount:
$300,000.00
Abstract:
DESCRIPTION (provided by applicant): Development of a vaccine to prevent, or reduce the rate of, HIV infections remains a high priority despite recent setbacks in the field. The lessons from failed and successful experimental programs indicate the need to
apply new approaches to HIV vaccine design… More
Oral, replicating Ad4-HIV vaccine development and evaluation in NHP challenge model
Award Year / Program / Phase:
2012 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Marc J. Gurwith – 858-450-9595
Award Amount:
$2,971,235.00
Abstract:
DESCRIPTION (provided by applicant): Development of a vaccine to prevent, or reduce the rate of, HIV infections remains a high priority despite recent setbacks in the field. The lessons from failed and successful experimental programs indicate the need toapply new approaches to HIV vaccine design… More
Replicating Ad4-HIV vaccine development based on improved HIV Env and GBV-C E2
Award Year / Program / Phase:
2012 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Jeffery Alexander – 858-450-9595
Award Amount:
$548,822.00
Abstract:
DESCRIPTION (provided by applicant): Development of a vaccine to prevent, or reduce the rate of, HIV infections remains a high priority despite recent setbacks in the field. The lessons from failed and successful experimental programs indicate the need toapply new approaches to HIV vaccine design… More
Use of Spray-Drying as a Manufacturing Process for Oral Adenovirus Vaccine
Award Year / Program / Phase:
2012 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Amish Patel – 858-450-9595
Award Amount:
$298,464.00
Abstract:
DESCRIPTION (provided by applicant): The 2009 H1N1 pandemic illustrates a critical weakness in our ability to respond to a pandemic threat. The ability to ramp up production of vaccine doses within the critical period from the discovery of the threat is hindered by two major supply constrictions: 1)… More